BRPI0519085A2 - processos para a fabricaÇço de azd0530 e para a fabricaÇço de uma quinazolina, intermediÁrio, processo para a fabricaÇço de quinazolinona, forma cristalina substancialmente homogÊnea de 4-(6-cloro 2, 3-metileno-diàxi-anilino) - 7 - {2- (4-metil-piperazin -1- il) - etàxi} - 5 - tetraidropiran - 4-il- àxi - quinazolina, e, composiÇço farmacÊutica - Google Patents
processos para a fabricaÇço de azd0530 e para a fabricaÇço de uma quinazolina, intermediÁrio, processo para a fabricaÇço de quinazolinona, forma cristalina substancialmente homogÊnea de 4-(6-cloro 2, 3-metileno-diàxi-anilino) - 7 - {2- (4-metil-piperazin -1- il) - etàxi} - 5 - tetraidropiran - 4-il- àxi - quinazolina, e, composiÇço farmacÊuticaInfo
- Publication number
- BRPI0519085A2 BRPI0519085A2 BRPI0519085-1A BRPI0519085A BRPI0519085A2 BR PI0519085 A2 BRPI0519085 A2 BR PI0519085A2 BR PI0519085 A BRPI0519085 A BR PI0519085A BR PI0519085 A2 BRPI0519085 A2 BR PI0519085A2
- Authority
- BR
- Brazil
- Prior art keywords
- manufacture
- quinazoline
- processes
- piperazin
- chloro
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title abstract 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title abstract 2
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 title 1
- 229950009919 saracatinib Drugs 0.000 title 1
- 239000000543 intermediate Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 238000001311 chemical methods and process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000004684 trihydrates Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0427697.8A GB0427697D0 (en) | 2004-12-17 | 2004-12-17 | Chemical process |
| PCT/GB2005/004807 WO2006064217A2 (en) | 2004-12-17 | 2005-12-14 | PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0519085A2 true BRPI0519085A2 (pt) | 2008-12-23 |
Family
ID=34090249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0519085-1A BRPI0519085A2 (pt) | 2004-12-17 | 2005-12-14 | processos para a fabricaÇço de azd0530 e para a fabricaÇço de uma quinazolina, intermediÁrio, processo para a fabricaÇço de quinazolinona, forma cristalina substancialmente homogÊnea de 4-(6-cloro 2, 3-metileno-diàxi-anilino) - 7 - {2- (4-metil-piperazin -1- il) - etàxi} - 5 - tetraidropiran - 4-il- àxi - quinazolina, e, composiÇço farmacÊutica |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8304417B2 (https=) |
| EP (1) | EP1871769B1 (https=) |
| JP (2) | JP5161584B2 (https=) |
| KR (6) | KR20080094847A (https=) |
| CN (1) | CN101115744B (https=) |
| AU (2) | AU2005315458B2 (https=) |
| BR (1) | BRPI0519085A2 (https=) |
| CA (2) | CA2590735C (https=) |
| ES (1) | ES2622480T3 (https=) |
| GB (1) | GB0427697D0 (https=) |
| IL (1) | IL183525A0 (https=) |
| MX (1) | MX2007007210A (https=) |
| NO (1) | NO20072755L (https=) |
| NZ (1) | NZ555468A (https=) |
| WO (1) | WO2006064217A2 (https=) |
| ZA (1) | ZA200704532B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0412074D0 (en) * | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
| WO2009068906A2 (en) * | 2007-11-26 | 2009-06-04 | Astrazeneca Ab | Combinations comprising zd4054 and a src family kinase inhibitor 172 |
| CN103275072B (zh) * | 2013-05-22 | 2016-01-20 | 苏州明锐医药科技有限公司 | 塞卡替尼的制备方法 |
| US11241434B2 (en) | 2013-06-13 | 2022-02-08 | Yale Uninversity | Compositions and methods for improving cognition in a subject |
| US10660957B2 (en) * | 2013-06-13 | 2020-05-26 | Yale University | Compositions and methods for treating an Aβ-modulated disease or disorder or improving cognition in a subject |
| US10369152B2 (en) | 2015-02-13 | 2019-08-06 | The Brigham And Women's Hospital, Inc. | Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue |
| PT3930715T (pt) | 2019-02-27 | 2024-08-02 | Astrazeneca Ab | Saracatinib para uso no tratamento de fibrose pulmonar idiopática |
| CN116332789A (zh) * | 2023-03-10 | 2023-06-27 | 上海康鹏科技股份有限公司 | 一种4-氨基-2-氟苯甲酰胺的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| CA2419301C (en) | 2000-08-21 | 2009-12-08 | Astrazeneca Ab | Quinazoline derivatives |
| DE60229046D1 (de) | 2001-04-19 | 2008-11-06 | Astrazeneca Ab | Chinazolin derivate |
| RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| GB0226434D0 (en) | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| GB0307333D0 (en) | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
-
2004
- 2004-12-17 GB GBGB0427697.8A patent/GB0427697D0/en not_active Ceased
-
2005
- 2005-12-14 KR KR1020087023971A patent/KR20080094847A/ko not_active Withdrawn
- 2005-12-14 AU AU2005315458A patent/AU2005315458B2/en not_active Expired
- 2005-12-14 US US11/793,064 patent/US8304417B2/en active Active
- 2005-12-14 CA CA002590735A patent/CA2590735C/en not_active Expired - Lifetime
- 2005-12-14 KR KR1020087023973A patent/KR20080094849A/ko not_active Withdrawn
- 2005-12-14 CA CA002675642A patent/CA2675642A1/en not_active Abandoned
- 2005-12-14 ES ES05818127.2T patent/ES2622480T3/es not_active Expired - Lifetime
- 2005-12-14 KR KR1020077015972A patent/KR20070090004A/ko not_active Ceased
- 2005-12-14 JP JP2007546172A patent/JP5161584B2/ja not_active Expired - Lifetime
- 2005-12-14 WO PCT/GB2005/004807 patent/WO2006064217A2/en not_active Ceased
- 2005-12-14 KR KR1020117022793A patent/KR20110114727A/ko not_active Ceased
- 2005-12-14 KR KR1020087023969A patent/KR20080094846A/ko not_active Withdrawn
- 2005-12-14 EP EP05818127.2A patent/EP1871769B1/en not_active Expired - Lifetime
- 2005-12-14 MX MX2007007210A patent/MX2007007210A/es not_active Application Discontinuation
- 2005-12-14 BR BRPI0519085-1A patent/BRPI0519085A2/pt not_active IP Right Cessation
- 2005-12-14 CN CN2005800476248A patent/CN101115744B/zh not_active Expired - Lifetime
- 2005-12-14 NZ NZ555468A patent/NZ555468A/en not_active IP Right Cessation
- 2005-12-14 KR KR1020087023972A patent/KR20080094848A/ko not_active Withdrawn
-
2007
- 2007-05-29 IL IL183525A patent/IL183525A0/en unknown
- 2007-05-30 NO NO20072755A patent/NO20072755L/no not_active Application Discontinuation
- 2007-05-31 ZA ZA200704532A patent/ZA200704532B/en unknown
-
2008
- 2008-12-15 JP JP2008318186A patent/JP2009143920A/ja active Pending
-
2009
- 2009-02-18 AU AU2009200622A patent/AU2009200622A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200704532B (en) | 2008-07-30 |
| CN101115744A (zh) | 2008-01-30 |
| KR20080094847A (ko) | 2008-10-24 |
| US8304417B2 (en) | 2012-11-06 |
| EP1871769A2 (en) | 2008-01-02 |
| KR20080094846A (ko) | 2008-10-24 |
| KR20110114727A (ko) | 2011-10-19 |
| US20090099196A1 (en) | 2009-04-16 |
| CA2675642A1 (en) | 2006-06-22 |
| EP1871769B1 (en) | 2017-02-22 |
| JP5161584B2 (ja) | 2013-03-13 |
| KR20080094849A (ko) | 2008-10-24 |
| AU2005315458B2 (en) | 2009-03-12 |
| AU2005315458A1 (en) | 2006-06-22 |
| CA2590735C (en) | 2009-11-10 |
| NZ555468A (en) | 2010-12-24 |
| WO2006064217A3 (en) | 2006-12-21 |
| WO2006064217A2 (en) | 2006-06-22 |
| WO2006064217A8 (en) | 2007-07-05 |
| MX2007007210A (es) | 2007-11-07 |
| IL183525A0 (en) | 2007-09-20 |
| AU2009200622A1 (en) | 2009-03-12 |
| KR20070090004A (ko) | 2007-09-04 |
| JP2008524183A (ja) | 2008-07-10 |
| CA2590735A1 (en) | 2006-06-22 |
| CN101115744B (zh) | 2012-02-01 |
| JP2009143920A (ja) | 2009-07-02 |
| NO20072755L (no) | 2007-07-02 |
| ES2622480T3 (es) | 2017-07-06 |
| KR20080094848A (ko) | 2008-10-24 |
| GB0427697D0 (en) | 2005-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0709633B8 (pt) | derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos | |
| BRPI0919873B8 (pt) | compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas | |
| PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
| TN2011000244A1 (en) | Organic compounds | |
| ECSP088563A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| PE20090210A1 (es) | Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa | |
| ATE400570T1 (de) | 2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs | |
| BRPI0519085A2 (pt) | processos para a fabricaÇço de azd0530 e para a fabricaÇço de uma quinazolina, intermediÁrio, processo para a fabricaÇço de quinazolinona, forma cristalina substancialmente homogÊnea de 4-(6-cloro 2, 3-metileno-diàxi-anilino) - 7 - {2- (4-metil-piperazin -1- il) - etàxi} - 5 - tetraidropiran - 4-il- àxi - quinazolina, e, composiÇço farmacÊutica | |
| MA32391B1 (fr) | Activateurs de la glucokinase | |
| BRPI0512790A (pt) | derivados de 2-alquil quinazolinona substituìdos como inibidores de parp | |
| BRPI0611350B8 (pt) | formulação, seus usos e seu processo de fabricação,e artigo de fabricação | |
| UY32648A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades | |
| BRPI0406762A (pt) | Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça | |
| AR031248A1 (es) | Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos | |
| PE20130188A1 (es) | Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk | |
| PE20090288A1 (es) | Derivados de quinoxalina como inhibidores de la pi3 quinasa | |
| BRPI0512335A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização | |
| MX2010003849A (es) | Antagonistas de cgrp. | |
| BRPI0613570A8 (pt) | composto ou um sal do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto. | |
| TW200606151A (en) | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | |
| AR079497A1 (es) | Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a | |
| ATE554086T1 (de) | Scopin-salze und deren verwendung in verfahren zur herstellung von n-demethyl-tiotropium und tiotropiumbromid | |
| UY32381A (es) | Derivados de quinazolinona utiles como antagonistas de vanillioides | |
| PE20090679A1 (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3 | |
| DOP2009000073A (es) | Inhibidores de cinasa que catalizan la transferencia de fosforilo y/o que enlazan nucleótidos atp/gtp. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |